Pulmonx Announces Online Publication Of Results From CONVERT Trial Evaluating AeriSeal System In Patients With Severe Emphysema And Collateral Ventilation

Benzinga · 1d ago

Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the online publication of results from the CONVERT Trial evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation, in Respiration: International Journal of Thoracic Medicine.

Bronchoscopic lung volume reduction with Zephyr® Endobronchial Valves is effective in patients with little to no collateral ventilation (CV-) in the targeted lung lobe. Collateral ventilation (CV+) allows airflow through openings in the fissures between lung lobes and can prevent a targeted lobe from reducing in volume following valve placement. The CONVERT Trial evaluated whether targeted treatment with the AeriSeal System could close these collateral channels and convert lobes from CV+ to CV- status, potentially enabling subsequent treatment with Zephyr Valves. The CONVERT study was conducted at 14 investigational sites in Europe and Australia and included 101 patients in the intent-to-treat population.

In the prospective, multicenter CONVERT Trial, 75.8% of evaluable patients (75 of 99) successfully had a CV+ lobe converted to CV- status following AeriSeal treatment.

Patients who successfully converted were subsequently treated with Zephyr Valves, and results were similar to published results in natively CV- lobes. At 45 days following valve placement, 88.9% of evaluable patients achieved clinically significant target lobe volume reduction which persisted through 12 months.

Patients also experienced improvements in measures of hyperinflation, lung function, quality of life and breathlessness following treatment with Zephyr Valves.